HB-EGF, Transactivation, and Cardiac Hypertrophy
SUMMARY
Transactivation of epidermal growth factor receptor (EGFR) family ligands by G protein coupled receptor (GPCR) agonist plays important roles in many physiologic activities. In the heart, heparin-binding EGF-like growth factor (HB-EGF), which is one of the EGF family ligands, is an indispensable molecule for cardiac cell metabolism. Membrane-anchored HB-EGF is released by GPCR agonist stimulation and moves signals leading to hypertrophy. Amelioration of this signal transduction by HB-EGF genome deletion causes severe heart dysfunction, indicating the important role of HB-EGF in the heart. Cleavage of HB-EGF was mediated by activation of membrane-anchored metalloprotease. Inhibitor of metalloprotease prevents activation of HB-EGF andattenuates hypertrophic response of cardiomyocytes by GPCR agonists such as angiotensin II or catecholamine. These data strongly suggest that HB-EGF is involved in cardiac development and metabolism. The physiologicand clinical roles of EGF family ligands in the heart are reviewed.
Key Words: cardiac hypertrophy , heart failure , HB-EGF , metalloprotease
No full text is available. To read the body of this article, please view the PDF online.
PII: S1873-9598(08)70018-8
doi:10.1016/S1873-9598(08)70018-8
© 2007 Elsevier B.V. All rights reserved.
